140 related articles for article (PubMed ID: 25682080)
1. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
[TBL] [Abstract][Full Text] [Related]
2. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Schmitz P; Gerber U; Schütze N; Jüngel E; Blaheta R; Naggi A; Torri G; Bendas G
Thromb Haemost; 2013 Nov; 110(5):1046-54. PubMed ID: 24009013
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
[TBL] [Abstract][Full Text] [Related]
4. Binding between heparin and the integrin VLA-4.
Schlesinger M; Simonis D; Schmitz P; Fritzsche J; Bendas G
Thromb Haemost; 2009 Nov; 102(5):816-22. PubMed ID: 19888514
[TBL] [Abstract][Full Text] [Related]
5. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Fritzsche J; Simonis D; Bendas G
Thromb Haemost; 2008 Dec; 100(6):1166-75. PubMed ID: 19132244
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
8. Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms.
Katz BZ; Muhl L; Zwang E; Ilan N; Herishanu Y; Deutsch V; Naparstek E; Vlodavsky I; Preissner KT
Thromb Haemost; 2007 Dec; 98(6):1193-9. PubMed ID: 18064313
[TBL] [Abstract][Full Text] [Related]
9. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers.
Klemke M; Weschenfelder T; Konstandin MH; Samstag Y
J Cell Physiol; 2007 Aug; 212(2):368-74. PubMed ID: 17352405
[TBL] [Abstract][Full Text] [Related]
10. Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Hoß SG; Grundmann M; Benkel T; Gockel L; Schwarz S; Kostenis E; Schlesinger M; Ilan N; Vlodavsky I; Bendas G
Thromb Haemost; 2018 Oct; 118(10):1803-1814. PubMed ID: 30235481
[TBL] [Abstract][Full Text] [Related]
11. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics.
Gockel LM; Heyes M; Li H; Al Nahain A; Gorzelanny C; Schlesinger M; Holdenrieder S; Li JP; Ferro V; Bendas G
ACS Appl Mater Interfaces; 2021 Feb; 13(6):7080-7093. PubMed ID: 33533245
[TBL] [Abstract][Full Text] [Related]
13. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
14. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells.
Irimura T; Nakajima M; Nicolson GL
Biochemistry; 1986 Sep; 25(18):5322-8. PubMed ID: 3768351
[TBL] [Abstract][Full Text] [Related]
15. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.
Reiland J; Kempf D; Roy M; Denkins Y; Marchetti D
Neoplasia; 2006 Jul; 8(7):596-606. PubMed ID: 16867222
[TBL] [Abstract][Full Text] [Related]
16. Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?
Li JP
Anticancer Agents Med Chem; 2008 Jan; 8(1):64-76. PubMed ID: 18220506
[TBL] [Abstract][Full Text] [Related]
17. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
[TBL] [Abstract][Full Text] [Related]
18. Heparanases and tumor metastasis.
Nakajima M; Irimura T; Nicolson GL
J Cell Biochem; 1988 Feb; 36(2):157-67. PubMed ID: 3281960
[TBL] [Abstract][Full Text] [Related]
19. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
Gandoglia I; Ivaldi F; Carrega P; Armentani E; Ferlazzo G; Mancardi G; Kerlero de Rosbo N; Uccelli A; Laroni A
Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
[TBL] [Abstract][Full Text] [Related]
20. The impact of heparanese and heparin on cancer metastasis and angiogenesis.
Vlodavsky I; Abboud-Jarrous G; Elkin M; Naggi A; Casu B; Sasisekharan R; Ilan N
Pathophysiol Haemost Thromb; 2006; 35(1-2):116-27. PubMed ID: 16855356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]